Global Dengue Vaccine Market Segmentation, By Type (Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, and Nucleic Acid Based Vaccine), Treatment (Diuretic, Anti-Allergic, Blood Thinners, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
Dengue Vaccine Market Analysis
The dengue vaccine market is experiencing significant growth due to the increasing incidence of dengue fever globally. This mosquito-borne viral infection poses a major public health challenge, particularly in tropical and subtropical regions. The market is driven by rising awareness of preventive healthcare and the need for effective vaccination to curb the spread of the disease. Recent developments include the approval and launch of innovative vaccines, such as Dengvaxia and Qdenga, which offer effective protection against multiple dengue virus serotypes. The growing investment in research and development by pharmaceutical companies, alongside government initiatives to promote vaccination campaigns, is expected to further enhance market expansion. As global travel increases and climate change affects mosquito populations, the demand for dengue vaccines is projected to rise, presenting significant opportunities for market players and stakeholders in the healthcare sector.
Dengue Vaccine Market Size
The global dengue vaccine market size was valued at USD 592.01 million in 2023 and is projected to reach USD 1434.67 million by 2031, with a CAGR of 11.70% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dengue Vaccine Market Trends
“Growing Adoption of Dengue Vaccination Programs”
The dengue vaccine market is witnessing notable trends driven by increased awareness and the rising incidence of dengue fever worldwide. Innovations in vaccine development, such as the introduction of tetravalent vaccines that protect against all four dengue virus serotypes, are enhancing efficacy and safety profiles. One significant trend is the growing adoption of dengue vaccination programs in endemic regions, particularly in Southeast Asia and Latin America, where health authorities are prioritizing preventive measures. Furthermore, collaboration between pharmaceutical companies and governments is fostering accelerated vaccine distribution and accessibility. As the market evolves, the emphasis on comprehensive vaccination strategies and community engagement will be pivotal in controlling dengue outbreaks and improving public health outcomes.
Report Scope and Dengue Vaccine Market Segmentation
|
Attributes
|
Dengue Vaccine Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), GSK plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), BIO-MED (India), Intercept Pharmaceuticals, Inc. (U.K.), Emcure Pharmaceuticals Ltd (India), Changchun BCHT Biotechnology Co. (China), Novo Medi Sciences Pvt. Ltd. (India)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Dengue Vaccine Market Definition
A dengue vaccine is a medical product designed to prevent dengue fever, a viral infection transmitted by mosquitoes. The vaccine stimulates the immune system to produce antibodies against the dengue virus, which can reduce the severity of the disease or prevent infection altogether. Dengue vaccines typically target all four serotypes of the virus, as infection with one serotype does not provide immunity against the others.
Dengue Vaccine Market Dynamics
Drivers
- Rising Incidence of Dengue
The rising incidence of dengue outbreaks worldwide, especially in tropical and subtropical regions, significantly fuels the demand for effective vaccination as a preventive measure. These outbreaks have become more frequent due to factors such as climate change, urbanization, and population growth, leading to ideal breeding conditions for the Aedes mosquitoes that transmit the dengue virus. As a result, more individuals are becoming aware of the potential severity of dengue, including its ability to cause severe complications and even death. This growing recognition of the disease’s risks is prompting governments and health organizations to prioritize vaccination programs as a key strategy for controlling outbreaks. Consequently, the need for safe and effective dengue vaccines is increasing, driving market growth and attracting investments in research and development.
- Government Initiatives and Funding
Increased government funding for dengue prevention and vaccination initiatives, coupled with supportive policies and regulations, plays a crucial role in driving market growth. Recognizing the public health threat posed by dengue fever, governments in endemic regions are allocating more resources to combat the disease through vaccination programs. These funds are used to enhance research and development efforts, enabling the creation of more effective vaccines. In addition, supportive regulatory frameworks streamline the approval process for new vaccines, facilitating quicker market entry. Governments are also launching public awareness campaigns to educate communities about the benefits of vaccination, further driving demand. This commitment to dengue prevention improves health outcomes and encourages pharmaceutical companies to invest in innovative solutions, thereby expanding the market landscape for dengue vaccines.
Opportunities
- Innovative Vaccine Development
The ongoing advancements in vaccine technology, particularly in areas such as mRNA and viral vector platforms, present substantial opportunities for the development of more effective and safer dengue vaccines. These innovative technologies allow for a more targeted immune response, potentially enhancing the immunogenicity of vaccines and providing longer-lasting protection against the dengue virus. The ability to rapidly design and modify vaccines using these platforms means that manufacturers can respond more swiftly to emerging strains and outbreaks. Furthermore, the incorporation of novel adjuvants and delivery methods can further improve vaccine efficacy and safety profiles. As research continues to unfold in this arena, there is a significant potential to create vaccines that prevent dengue and minimize adverse reactions, thereby boosting public confidence and uptake.
- Rising Awareness and Education in Dengue Vaccination
Increased public awareness regarding the significance of dengue vaccination, particularly in endemic regions, presents a valuable opportunity for boosting vaccine uptake. Educational campaigns aimed at informing communities about the dangers of dengue and the benefits of vaccination can play a crucial role in encouraging participation in vaccination programs. By disseminating information through various channels—such as social media, community health workshops, and partnerships with local healthcare providers—public health organizations can effectively engage populations at risk. This heightened awareness fosters a sense of community responsibility and empowers individuals to make informed health choices. As communities become more proactive about dengue prevention, the demand for vaccines is likely to rise, consequently driving market growth and contributing to improved public health outcomes.
Restraints/Challenges
- Cost of Vaccination Programs
The financial burden of implementing vaccination programs, particularly in low-income countries, poses a significant challenge to the dengue vaccine market. Many governments operate within limited budgets, which may restrict their capacity to launch comprehensive vaccination initiatives. These financial constraints can lead to inadequate funding for public health campaigns, affecting vaccine accessibility and distribution. Furthermore, the costs associated with vaccine procurement, storage, and administration add additional strain on already stretched healthcare budgets. As a result, low-income regions may experience delays in vaccine rollout, limiting the population's access to essential preventive measures against dengue fever. Consequently, this financial barrier can hinder overall market growth and effectiveness in combating dengue outbreaks, underscoring the need for sustainable funding solutions.
- Distribution and Cold Chain Logistics
Vaccines typically require refrigeration to preserve their efficacy, which can be particularly difficult to achieve in remote or low-resource areas where infrastructure may be lacking. In many developing regions, inadequate cold chain systems can hinder the effective distribution of dengue vaccines, leading to potential spoilage or loss of potency during transit. This logistical challenge affects vaccine availability and raises concerns about vaccine safety and efficacy, ultimately impacting public trust in vaccination programs. Addressing these cold chain infrastructure issues is crucial for ensuring that dengue vaccines reach the populations that need them most, thereby limiting their impact on overall market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Dengue Vaccine Market Scope
The market is segmented on the basis of type, treatment, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Live Attenuated Vaccine
- Chimeric Live Attenuated Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Nucleic Acid Based Vaccine
Treatment
- Diuretic
- Anti-Allergic
- Blood Thinners
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Dengue Vaccine Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the market due to the presence of key industry players. In addition, the rising incidence of dengue cases in the region has further fueled market expansion. This combination of factors positions North America as a key player in the ongoing development and distribution of dengue vaccines.
The Asia-Pacific region leads the dengue vaccine market, primarily due to heightened government spending aimed at improving healthcare infrastructure. This increased investment facilitates the development and distribution of advanced healthcare solutions, including vaccines. As a result, the region is well-positioned to address the growing demand for effective dengue prevention measures.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Dengue Vaccine Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Dengue Vaccine Market Leaders Operating in the Market Are:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- GSK plc (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- BIO-MED (India)
- Intercept Pharmaceuticals, Inc. (U.K.)
- Emcure Pharmaceuticals Ltd (India)
- Changchun BCHT Biotechnology Co. (China)
- Novo Medi Sciences Pvt. Ltd. (India)
Latest Developments in Dengue Vaccine Market
- In February 2024, Takeda and Biological E announced a collaboration to produce 50 million dengue vaccines, enhancing efforts to combat the disease. In addition, Miltenyi Biotec unveiled the Hyderabad Center for Cell and Gene Therapy Services, focusing on advanced therapeutic solutions. The BioAsia 2024 event showcased significant breakthroughs in the pharmaceutical industry, highlighting innovations and advancements in healthcare
- In April 2023, health authorities in Argentina approved the use of a Japanese dengue vaccine, which requires administration in two doses spaced three months apart. This decision marks a significant step in enhancing dengue prevention efforts within the country. The two-dose regimen is designed to ensure optimal immunity against the disease
- In May 2023, Takeda announced that its dengue vaccine, QDENGA®, received multiple approvals, including one from Brazil's National Health Surveillance Agency in March 2023. This approval permits the vaccine's use in individuals aged 4 to 60 years, offering protection against all four dengue virus serotypes. Takeda's advancements in securing these approvals demonstrate its ongoing efforts to combat dengue fever effectively
- In March 2021, Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate, TAK-003, received approval from the European Medicines Agency (EMA) for use in preventing outbreaks among individuals aged 4 to 60. The company plans to seek regulatory approvals for this vaccine in several countries, including Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand throughout 2021. This move reflects Takeda's commitment to expanding access to dengue prevention globally
SKU-